This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

1018 ISS

Dynavax Technologies Corporation

Drug Names(s): ISS-1018

Description: Dynavax Technologies is developing short, immunostimulatory DNA sequences (ISS). 1018 ISS is a CpG oligodeoxynucleotides (CpG-ODNs). CpG-ODNs affect innate and adaptive immune responses, including antigen presentation, costimulatory molecule expression, dendritic cell maturation, and induction of cytokines enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).

1018 ISS News

Pink Sheet Novel Biologics Will Get Suffixes (Or At Least One Did)

Pink Sheet Keeping Track: A Second Straight Burst Of FDA Approvals

Pink Sheet Keeping Track: A Massive Week Of Agency Approvals

Pink Sheet Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug